SER SERINA THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, SERINA THERAPEUTICS INC reported revenue of $0 (down 100.0% from a year earlier), net income of −$6.36M and diluted EPS of −$0.55; for the fiscal year ended December 2025 revenue was $130K, up 132.1% on the year before.

SER annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $130K, gross profit n/a, operating income −$24.0M, net income −$19.2M (margin -14755.4%), EPS −$1.91
• Fiscal year ended Dec 2024: revenue $56.0K, gross profit n/a, operating income −$17.0M, net income −$11.1M (margin -19894.6%), EPS −$1.51
• Fiscal year ended Dec 2023: revenue $3.15M, gross profit $102K, operating income −$3.13M, net income $5.27M (margin 167.1%), EPS $0.73
• Fiscal year ended Dec 2022: revenue $34.0K, gross profit $21.0K, operating income −$6.98M, net income −$10.5M (margin -30770.6%), EPS −$9.70
• Fiscal year ended Dec 2021: revenue $144K, gross profit $125K, operating income −$7.93M, net income −$8.68M (margin -6024.3%), EPS −$0.23

SER quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $0 (down 100.0% year over year), net income −$6.36M, EPS −$0.55
• Quarter ended Mar 31, 2026: revenue n/a, net income −$6.90M, EPS −$0.58
• Quarter ended Dec 31, 2025 (from the annual report): revenue $0 (up 100.0% year over year), net income −$3.34M, EPS −$0.31
• Quarter ended Sep 30, 2025: revenue $0 (down 100.0% year over year), net income −$4.59M, EPS −$0.45
• Quarter ended Jun 30, 2025: revenue $130K (up 154.9% year over year), net income −$6.45M, EPS −$0.66
• Quarter ended Mar 31, 2025: revenue $0 (down 100.0% year over year), net income −$4.81M, EPS −$0.49
• Quarter ended Dec 31, 2024 (from the annual report): revenue −$14.0K (down 100.5% year over year), net income −$2.74M, EPS $3.23
• Quarter ended Sep 30, 2024: revenue $14.0K (down 51.7% year over year), net income $1.41M, EPS $0.13
• Quarter ended Jun 30, 2024: revenue $51.0K (up 628.6% year over year), net income $5.20M, EPS $0.51
• Quarter ended Mar 31, 2024: revenue $5.00K (down 83.3% year over year), net income −$15.0M, EPS −$5.38
• Quarter ended Dec 31, 2023 (from the annual report): revenue $3.09M (up 38487.5% year over year), net income $1.05M, EPS $0.19
• Quarter ended Sep 30, 2023: revenue $29.0K (up 222.2% year over year), net income $1.75M, EPS $0.23
• Quarter ended Jun 30, 2023: revenue $7.00K (down 41.7% year over year), net income $808K, EPS $0.11
• Quarter ended Mar 31, 2023: revenue $30.0K (up 500.0% year over year), net income $1.66M, EPS $0.20
• Quarter ended Dec 31, 2022 (from the annual report): revenue $8.00K (down 70.4% year over year), net income −$2.70M, EPS n/a
• Quarter ended Sep 30, 2022: revenue $9.00K (down 62.5% year over year), net income −$2.44M, EPS −$0.06
• Quarter ended Jun 30, 2022: revenue $12.0K (down 67.6% year over year), net income −$2.62M, EPS −$0.07
• Quarter ended Mar 31, 2022: revenue $5.00K (down 91.1% year over year), net income −$2.71M, EPS n/a
• Quarter ended Dec 31, 2021 (from the annual report): revenue $27.0K, net income −$2.16M, EPS −$0.05
• Quarter ended Sep 30, 2021: revenue $24.0K, net income −$1.96M, EPS −$0.05

SER cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$18.0M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$17.1M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$2.48M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$5.94M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$7.86M, share buybacks n/a

SER balance sheet

• Jun 30, 2026: cash $23.0M, total assets $25.8M, total liabilities $7.08M, shareholders' equity n/a
• Mar 31, 2026: cash $24.5M, total assets $27.3M, total liabilities $9.67M, shareholders' equity n/a
• Dec 31, 2025: cash $3.06M, total assets $6.95M, total liabilities $6.99M, shareholders' equity −$37.0K
• Sep 30, 2025: cash $8.62M, total assets $12.4M, total liabilities $10.8M, shareholders' equity $1.76M
• Jun 30, 2025: cash $6.04M, total assets $8.94M, total liabilities $7.30M, shareholders' equity $1.80M
• Mar 31, 2025: cash $4.27M, total assets $6.73M, total liabilities $5.17M, shareholders' equity $1.70M
• Dec 31, 2024: cash $3.67M, total assets $6.72M, total liabilities $6.22M, shareholders' equity $641K
• Sep 30, 2024: cash $3.19M, total assets $7.44M, total liabilities $21.3M, shareholders' equity −$13.8M

What is SER's revenue?

SERINA THERAPEUTICS INC reported $130K of revenue for the fiscal year ended December 2025.

Is SER profitable?

No. SERINA THERAPEUTICS INC lost $21.2M over the last four quarters.

What is SER's EPS?

Diluted earnings per share over the last four quarters were −$1.89; −$0.55 in the latest quarter.

SER ownership and insider trades · All stocks